ondansetron and escitalopram

ondansetron has been researched along with escitalopram in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Bang-Andersen, B; Frederiksen, K; Hogg, S; Jensen, KG; Jørgensen, M; Mørk, A; Nielsen, SM; Ruhland, T; Smith, G; Stensbøl, TB; Zhong, H	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1

Reviews

1 review(s) available for ondansetron and escitalopram

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

2 other study(ies) available for ondansetron and escitalopram

Article	Year
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. Journal of medicinal chemistry, 2011, May-12, Volume: 54, Issue:9 Topics: Animals; Antidepressive Agents; Cell Line; Depressive Disorder, Major; Drug Partial Agonism; Drug Stability; Hippocampus; Humans; In Vitro Techniques; Microsomes, Liver; Oocytes; Piperazines; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Sulfides; Vortioxetine; Xenopus	2011

Article

Year

Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.

Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

Journal of medicinal chemistry, 2011, May-12, Volume: 54, Issue:9

Topics: Animals; Antidepressive Agents; Cell Line; Depressive Disorder, Major; Drug Partial Agonism; Drug Stability; Hippocampus; Humans; In Vitro Techniques; Microsomes, Liver; Oocytes; Piperazines; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Sulfides; Vortioxetine; Xenopus

2011